Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
J Korean Med Sci
; 39(6): e52, 2024 Feb 19.
Article
em En
| MEDLINE
| ID: mdl-38374626
ABSTRACT
BACKGROUND:
Current guidelines recommend using nirmatrelvir-ritonavir for coronavirus disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications limit its applicability in certain categories of patients. The aim of the study was to evaluate the real-world effectiveness of molnupiravir and nirmatrelvir-ritonavir in managing COVID-19 among hospitalized patients.METHODS:
We conducted a retrospective cohort study among hospitalized COVID-19 patients who received molnupiravir or nirmatrelvir-ritonavir and did not require baseline supplemental oxygen from February 2022 to January 2023. We compared the effectiveness of molnupiravir and nirmatrelvir-ritonavir with a focus on disease progression.RESULTS:
The study included 401 high-risk, hospitalized adult COVID-19 patients who received molnupiravir or nirmatrelvir-ritonavir. No significant difference was found in disease progression, the composite outcome of disease progression (4.0% vs. 1.4%, P = 0.782), and O2 supplementation via nasal prong (21.8% vs. 14.8%, P = 0.115) between the patients treated with molnupiravir and those treated with nirmatrelvir-ritonavir. This finding was similar after 11 propensity-score matching. In the multivariate analysis, molnupiravir treatment was not significantly associated with progression to severe disease.CONCLUSION:
In conclusion, our findings suggest that similar to nirmatrelvir-ritonavir, molnupiravir has a distinct potential role in COVID-19 treatment, transcending its current perceived status as only a secondary option.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Prolina
/
Citidina
/
COVID-19
/
Hidroxilaminas
/
Lactamas
/
Leucina
/
Nitrilas
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article